In a filing, Syndax Pharmaceuticals Inc revealed its Head of R&D, CMO Botwood Nicholas A.J. acquired Company’s shares for reported $0.11 million on May 16 ’25. In the deal valued at $8.99 per share,11,765 shares were bought. As a result of this transaction, Botwood Nicholas A.J. now holds 35,165 shares worth roughly $0.31 million.
Then, Huber Martin H. Jr. bought 5,000 shares, generating $44,950 in total proceeds. Upon buying the shares at $8.99, the Director now owns 79,000 shares.
Before that, Katkin Keith bought 10,000 shares. Syndax Pharmaceuticals Inc shares valued at $91,120 were divested by the Director at a price of $9.11 per share. As a result of the transaction, Katkin Keith now holds 100,000 shares, worth roughly $0.88 million.
UBS initiated its Syndax Pharmaceuticals Inc [SNDX] rating to a Buy in a research note published on October 24, 2024; the price target was $37. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late June with a ‘”a Buy”‘ rating. Scotiabank also remained covering SNDX and has decreased its forecast on January 31, 2024 with a “Sector perform” recommendation from previously “Sector outperform” rating. Mizuho started covering the stock on December 22, 2023. It rated SNDX as “a Buy”.
Price Performance Review of SNDX
On Tuesday, Syndax Pharmaceuticals Inc [NASDAQ:SNDX] saw its stock jump 0.23% to $8.75. Over the last five days, the stock has lost -6.57%. Syndax Pharmaceuticals Inc shares have fallen nearly -56.42% since the year began. Nevertheless, the stocks have fallen -33.81% over the past one year. While a 52-week high of $25.07 was reached on 02/21/25, a 52-week low of $8.58 was recorded on 05/15/25.
Levels Of Support And Resistance For SNDX Stock
The 24-hour chart illustrates a support level at 8.66, which if violated will result in even more drops to 8.56. On the upside, there is a resistance level at 8.90. A further resistance level may holdings at 9.04.
How much short interest is there in Syndax Pharmaceuticals Inc?
A steep rise in short interest was recorded in Syndax Pharmaceuticals Inc stocks on 2025-06-13, growing by 0.27 million shares to a total of 22.0 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 21.73 million shares. There was a rise of 1.22%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 25, 2023 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $29 price target.
